Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke
Ying Gao,Weiqi Chen,Yuesong Pan,Jing Jing,Chunjuan Wang,S Claiborne Johnston,Pierre Amarenco,Philip M Bath,Lingling Jiang,Yingying Yang,Tingting Wang,Shangrong Han,Xia Meng,Jinxi Lin,Xingquan Zhao,Liping Liu,Jinguo Zhao,Ying Li,Yingzhuo Zang,Shuo Zhang,Hongqin Yang,Jianbo Yang,Yuanwei Wang,Dali Li,Yanxia Wang,Dongqi Liu,Guangming Kang,Yongjun Wang,Yilong Wang,INSPIRES Investigators,Zhimin Wang,Jianmin Guo,Xiujuan Song,Xinqiang Wang,Weifeng Lu,Panbing Huang,Feng Li,Lihua Wang,Weigang Xiao,Yibin Cao,Liangqun Rong,Ying Xing,Lili Ma,Yanhua Zhou,YuQing Han,Jingxian Fang,Jie Liu,Wen Shangguan,Bin Liu,Jianhua Li,Yan Han,Chengguang Song,Xuhong Song,Yuanfeng Lv,Changqing Xu,Congmin Ma,Zhihui Duan,Yungao Pan,Lijie Ren,Bin Li,Jinqi Fan,Yuanren Zhang,Jingfang Li,Baojun Wang,Jun Gu,Xiaoping Yin,Xiao Wang,Liguo Chang,Kaoling Gong,Wenhua Zhang,Yu Che,Yinyuan Wan,Linying Gui,Ping Sun,Zhonghai Jia,Haichao Liu,Qinglian Meng,Donghe Chai,Lei Zhang,Guofeng Li,Huafeng Jin,Gexia Liu,Yonghong Tang,Xiaomin Mei,Guoping Zou,Yuefeng Yang,Quanhao Li,Xiju Tian,Hong Chen,Jialiang Xiao,Xiaoming Song,Guangning Li,Guozhong Li,Chunjie Yang,Xiting Zhang,Chun Wang,Jizheng Hu,Wei Hu,Zhen Jiao,Yunnan Lu,Zhangyong Xia,Yufen Wang,Yinshan Wang,Jinxing Qi,Xiaoping Wang,Shuqin Liu,Bo Li,Yinghui Li,Yaming Sun,Ping Jing,Jialing Wu,Bo Yang,Jinghua Zhang,Tianxia Zhang,Chunling Zheng,Lejun Li,Huimin Li,Fumin Yu,Shufang Yao,Jianjun Chang,Dongqun Li,Ganqin Du,Yi Zhao,Pengfei Liang,Ming Wang,Qi Fang,Youqing Deng,Xuzhao Gao,Runxiu Zhu,Yimin Xie,Yanshu Liu,Yi Yuan,Qiuyi Wu,Guimei Zhao,Yan Yang,Yong Lu,Weidong Zhao,Tianbao Chen,Deng Pan,Min Yang,Baoguo Xue,Ge Zhang,Yanjiang Zhao,Yunfei Wei,Wenwei Yun,Xiaoqi Chen,Danhong Wu,Lifang Zhang,Baoying Sheng,Zhigang Cui,Xiangdong Xie,Guanghui Cheng,Yifei Zhang,Ruiming Zhu,Yong Chen,GuoHua Liu,Lei Feng,Zhihua Long,Huisheng Chen,Ping Zhang,Yuanliang Cui,Yongli Zhang,Yazhou Han,Yajie Bai,Tieyu Tang,Songdi Wu,Wenping Gong,Jun Wang,Zhishan Zhu,Xiaoyan Ma,Leyi Yao,Runhui Li,Shuanggen Zhu,Juntao Li,Xiuhui Qi,Zhongping Jiang,Zhigang Liang,Chunping Liu,Dongjuan Xu,Tao Qiu,Chunping Chen,Hong Tan,Shengli Chen,Chunshui Yang,Wei Jun,Qing He,Zengqiang Sun,Shen Li,Cunju Guo,Hongliang Wang,Dongfang Li,Hongbin Wu,Wenxu Zhen,Lijun Wang,Wenke Hong,Xuerong Qiu,Xinxia Wei,Yongtao Lv,Xiangyang Feng,Gaiqing Yang,Songjun Lin,Aihua Cao,Dejin Sun,Pengcheng Fu,Wenfeng Cao,Wenjun Xue,Haiyan Liu,Shanshan Li,Fang Qu,Zhengguo Zhou,Ping Liu,Lixia Wang,Yiping Wu,Jinxing Liu,Xin Sun,Qingyong Wang,Xiaomei Li,Qizhang Wang,Yongxiong Wu,Chunfeng Liu,Yanxin Zhao,Zhijian Lin,Rui Ma,Jiedan Li,Zhishun Zhu,Lili Guo,Bing Sun,Jun Tan,Ke Yang,Yong Bi,Yingjie Duan,Shaochun Li,Xiaoliang Lou,Xiaosong Huang,Fucai Zang,Yonghua Dong,Jingyan Zhao,Yanzeng Cui,Zili Zhang,Yali Zhang,Peng Yan,Huixian Fan,Qiuhong Ji,Aisheng Wu,Xinshen Han,Philip M W Bath,David Wang,Hao Li,Haifeng Li,James Wang,Yuming Xu,Kehui Dong,Xiaoling Liao,Hui Qu,Li Liu,Jie Song,Shuting Liu,Xiaoyu Che,Xianhong Liang,Shangzhi Li,Nan Qi,Xiaolei Chen,Zhiyuan Ji,Jianying Li,Jiawei Lu,Long Wang,Jiandong Yu,Xiaowu Zhang,Hongyi Yan,Aoming Jin,Haibo Wu
DOI: https://doi.org/10.1056/NEJMoa2309137
2023-12-28
Abstract:Background: Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared with aspirin alone administered within 72 hours after the onset of acute cerebral ischemia from atherosclerosis has not been well studied. Methods: In 222 hospitals in China, we conducted a double-blind, randomized, placebo-controlled, two-by-two factorial trial involving patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause who had not undergone thrombolysis or thrombectomy. Patients were randomly assigned, in a 1:1 ratio, within 72 hours after symptom onset to receive clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21) or matching clopidogrel placebo plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90). There was no interaction between this component of the factorial trial design and a second part that compared immediate with delayed statin treatment (not reported here). The primary efficacy outcome was new stroke, and the primary safety outcome was moderate-to-severe bleeding - both assessed within 90 days. Results: A total of 6100 patients were enrolled, with 3050 assigned to each trial group. TIA was the qualifying event for enrollment in 13.1% of the patients. A total of 12.8% of the patients were assigned to a treatment group no more than 24 hours after stroke onset, and 87.2% were assigned after 24 hours and no more than 72 hours after stroke onset. A new stroke occurred in 222 patients (7.3%) in the clopidogrel-aspirin group and in 279 (9.2%) in the aspirin group (hazard ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.008). Moderate-to-severe bleeding occurred in 27 patients (0.9%) in the clopidogrel-aspirin group and in 13 (0.4%) in the aspirin group (hazard ratio, 2.08; 95% CI, 1.07 to 4.04; P = 0.03). Conclusions: Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset led to a lower risk of new stroke at 90 days than aspirin therapy alone but was associated with a low but higher risk of moderate-to-severe bleeding. (Funded by the National Natural Science Foundation of China and others; INSPIRES ClinicalTrials.gov number, NCT03635749.).